公开(公告)号：US20100272648A1

公开(公告)日：2010-10-28

申请号：US12772798

申请日：2010-05-03

申请人： Dennis C. Liotta ,  Raymond J. Dingledine ,  Stephen F. Traynelis

发明人： Dennis C. Liotta ,  Raymond J. Dingledine ,  Stephen F. Traynelis

IPC分类号： A61K49/00 ,  C12Q1/02

CPC分类号： G01N33/9406 ,  A61K49/0008 ,  G01N33/5058 ,  G01N33/5088 ,  G01N33/84 ,  G01N2800/2835 ,  G01N2800/2842 ,  G01N2800/2857 ,  G01N2800/2871

摘要： Processes are provided for the identification a compound that is useful to treat or prevent a disorder that lowers the pH in a region of affected tissue comprising assessing the difference in potency, or potency boost, of the compound at physiological pH versus disorder-induced pH in a cell that expresses a human NMDA receptor. The assessment of potency boost can include measuring an IC50 of a compound at physiological pH and at disorder-induced pH (the “potency boost”) until a 95% confidence interval for the potency boost does not change more than 15% with the addition of a new experiment, wherein the measurements are repeated at least 5 times. The processes can be used for the selection of safe NMDA receptor antagonists for the treatment or prevention of a human disorder that lowers the pH in a region affected tissue. Such disorders include, but are not limited to, neuropathic pain, ischemic, Parkinsons disease, epilepsy and traumatic brain injuries.

摘要翻译： 提供了用于鉴定化合物的方法，该化合物可用于治疗或预防降低受影响组织的区域中的pH的病症，包括评估化合物在生理pH下与药物诱导的pH下的效力或效力升高的差异 表达人NMDA受体的细胞。 效力增强的评估可以包括测量化合物在生理pH和无序诱导的pH（“效力促进”）下的IC 50，直到效力增强的95％置信区间随着添加 一个新的实验，其中测量重复至少5次。 该方法可用于选择安全NMDA受体拮抗剂，用于治疗或预防降低受影响组织区域pH的人类病症。 这些病症包括但不限于神经性疼痛，缺血性，帕金森病，癫痫和创伤性脑损伤。

公开(公告)号：US07795413B2

公开(公告)日：2010-09-14

申请号：US11767326

申请日：2007-06-22

申请人： Kenneth D. Wild, Jr. ,  James J. S. Treanor ,  Haichun Huang ,  Heather Inoue ,  Tie J. Zhang ,  Frank Martin

发明人： Kenneth D. Wild, Jr. ,  James J. S. Treanor ,  Haichun Huang ,  Heather Inoue ,  Tie J. Zhang ,  Frank Martin

IPC分类号： C07H21/04 ,  C12N15/00 ,  C12N5/06 ,  A61K39/395 ,  C12P21/08 ,  C07K16/00

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/74 ,  G01N2333/48 ,  G01N2800/2842

摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.

摘要翻译： 本发明提供与人神经生长因子（NGF）相互作用或结合的抗体，从而中和NGF的功能。 本发明还提供了所述抗体的药物组合物和中和NGF功能的方法，特别是通过施用药学上有效量的抗NGF抗体来治疗NGF相关疾病（例如慢性疼痛）。 还提供了使用抗NGF抗体检测样品中NGF量的方法。

公开(公告)号：US07794949B2

公开(公告)日：2010-09-14

申请号：US11115747

申请日：2005-04-27

申请人： Anthony J. Schaeffer ,  Alisa E. Koch

发明人： Anthony J. Schaeffer ,  Alisa E. Koch

IPC分类号： G01N33/53 ,  G01N33/00

CPC分类号： C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/52 ,  G01N2800/2842 ,  G01N2800/36

摘要： The present invention provides biomarkers of chronic pelvic pain syndrome for use in diagnosis, drug screening, therapy monitoring, research and therapeutic applications. In particular, the present invention provides MCP-1 and MIP-1α as biomarkers of chronic pelvic pain syndrome.

摘要翻译： 本发明提供用于诊断，药物筛选，治疗监测，研究和治疗应用的慢性盆腔疼痛综合征的生物标志物。 特别地，本发明提供MCP-1和MIP-1α作为慢性盆腔疼痛综合征的生物标志物。

公开(公告)号：US20100004171A1

公开(公告)日：2010-01-07

申请号：US12375634

申请日：2007-08-08

申请人： Nicolas G. Bazan ,  Jian-Guo Cui

发明人： Nicolas G. Bazan ,  Jian-Guo Cui

IPC分类号： A61K38/16 ,  A61K31/167 ,  C12Q1/02

CPC分类号： A61K38/1709 ,  G01N33/5058 ,  G01N2333/4722 ,  G01N2800/2842

摘要： The agrin protein was shown to be important in preventing the development of neuropathic pain, as well as in treating neuropathic pain. Both agrin protein and gene expression were shown to be down-regulated in mammals with neuropathic pain. Increasing either agrin gene expression or protein resulted in a decrease in the development of neuropathic pain. Agrin protein or the C-terminal agrin fragments can be administered in a number of ways, preferably by intrathecal injection. In addition, agrin can be increased by administering a compound shown to affect agrin gene expression or agrin protein concentration, e.g., SCP-I and SCP-M1 (also known as JMM). Agrin protein decrease was shown to be prevented by administering an NMDA receptor antagonist, e.g., MK801. Agrin and a C-terminal agrin fragment also induced phosphorylation of the NMDA receptor subunit NR1 at the serine residue site which led to suppression of neuropathic pain.

摘要翻译： 显示出集聚蛋白蛋白对于预防神经性疼痛的发展以及治疗神经性疼痛是重要的。 在具有神经性疼痛的哺乳动物中，集聚蛋白和基因表达都显示出下调。 增加集聚蛋白基因表达或蛋白质导致神经性疼痛发展的减少。 集聚蛋白或C末端集聚蛋白片段可以多种方式施用，优选通过鞘内注射。 此外，通过施用显示影响集聚蛋白基因表达或集聚蛋白浓度的化合物，例如SCP-1和SCP-M1（也称为JMM），可以增加集聚蛋白。 通过施用NMDA受体拮抗剂（例如MK801），可以防止集聚蛋白的降低。 集聚蛋白和C末端集聚蛋白片段还诱导丝氨酸残基部位的NMDA受体亚基NR1的磷酸化，导致神经性疼痛的抑制。

公开(公告)号：US20070298407A1

公开(公告)日：2007-12-27

申请号：US11449464

申请日：2006-06-08

申请人： William F. McKay ,  Jeffrey M. Gross ,  Hai Trieu ,  Josee Roy ,  Susan J. Drapeau ,  Michael J. Schendel ,  Andrew J. Lowenthal Walsh

发明人： William F. McKay ,  Jeffrey M. Gross ,  Hai Trieu ,  Josee Roy ,  Susan J. Drapeau ,  Michael J. Schendel ,  Andrew J. Lowenthal Walsh

IPC分类号： C12Q1/00

CPC分类号： G01N33/6896 ,  G01N2800/2842

摘要： The invention provides kits developed to analyze ex vivo, a sample retrieved from the area of the pathological condition for diagnosis and monitoring the pain generator(s) of axial pain with or without radiculopathy and methods for screening therapeutic compounds potentially useful for treating axial pain with or without radiculopathy. Alternatively, degenerated discs can be monitored and treated before occurrence of a pathological pain condition. Pain markers and markers of degenerating disc include markers of neuronal, vascular, immune and matrix elements.

摘要翻译： 本发明提供开发用于离体分析的试剂盒，从用于诊断和监测具有或不具有神经根病变的疼痛发生器的疼痛发生器的病理状况区域获取的样品以及用于筛选潜在地可用于治疗轴向疼痛的治疗化合物的方法 或没有神经根病。 或者，可以在发生病理性疼痛状况之前监测和治疗退化的椎间盘。 退行性椎间盘的疼痛标志物和标志物包括神经元，血管，免疫和基质元件的标记物。

公开(公告)号：US20070179102A1

公开(公告)日：2007-08-02

申请号：US11232776

申请日：2005-09-22

申请人： Inmaculada Silos-Santiago ,  Julie Rosenfeld

发明人： Inmaculada Silos-Santiago ,  Julie Rosenfeld

IPC分类号： A61K48/00 ,  C12Q1/68 ,  G01N33/567

CPC分类号： G01N33/6896 ,  G01N2500/10 ,  G01N2800/2842

摘要： The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders. The invention further provides methods for identifying a compound capable of treating a pain disorder. In addition, the invention provides a method for treating a subject having a pain disorder, e.g., a pain disorder characterized by aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 polypeptide activity or aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 nucleic acid expression.

摘要翻译： 本发明涉及用于治疗和诊断疼痛障碍的方法和组合物。 本发明还提供了鉴定能够治疗疼痛障碍的化合物的方法。 此外，本发明提供了治疗患有疼痛障碍的受试者的方法，例如以异常9805,2047,46566,57749,577,20739,57145,1465,1587,2146,2207,32838,336为特征的疼痛病症 和52908多肽活性或异常9805,2047,46566,57749,577,20739,57145,1465,1587,2166,2207,32838,336和52908核酸表达。

公开(公告)号：US20060251648A1

公开(公告)日：2006-11-09

申请号：US11384955

申请日：2006-03-20

申请人： Stuart Bevan ,  Pamposh Ganju ,  Peter McIntyre ,  Ardem Patapoutian ,  Andrea Peier ,  Chuanzheng Song

发明人： Stuart Bevan ,  Pamposh Ganju ,  Peter McIntyre ,  Ardem Patapoutian ,  Andrea Peier ,  Chuanzheng Song

IPC分类号： G01N33/53 ,  C07H21/04 ,  A61K48/00 ,  C12P21/06 ,  A61K39/395 ,  C07K14/705 ,  A61K31/16

CPC分类号： C07K14/705 ,  C12Q1/6886 ,  G01N33/6872 ,  G01N33/6896 ,  G01N2500/00 ,  G01N2800/2842 ,  G01N2800/52

摘要： This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.

摘要翻译： 本发明提供瞬时受体潜在通道家族的新基因和多肽，以及这些基因和多肽用于治疗疼痛和鉴定用于治疗疼痛的药剂的用途。

公开(公告)号：US20050074819A1

公开(公告)日：2005-04-07

申请号：US10676289

申请日：2003-10-01

申请人： Kazuhide Inoue ,  Makoto Tsuda ,  Schuichi Koizumi ,  Shinichi Kohsaka

发明人： Kazuhide Inoue ,  Makoto Tsuda ,  Schuichi Koizumi ,  Shinichi Kohsaka

IPC分类号： A61K31/7088 ,  A61K39/395 ,  A61K48/00 ,  A61P25/02 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/566 ,  G01N33/567 ,  G01N33/68

CPC分类号： G01N33/6896 ,  G01N2800/2842

摘要： The present invention relates to a screening method for a compound useful for treatment of neuropathic pain, and therapy for the treatment of neuropathic pain. The screening method comprises determining inhibitory activity on the action of P2X4 receptor or inhibitory activity on the activation of microglia, of test compounds. The pharmaceutical composition and the therapy employ a P2X4 receptor inhibitor or a microglial activation-inhibitor as active ingredient.

摘要翻译： 本发明涉及用于治疗神经性疼痛的化合物的筛选方法和治疗神经性疼痛的疗法。 该筛选方法包括测定P2X4受体的作用或测试化合物对小胶质细胞的活化的抑制活性的抑制活性。 药物组合物和治疗使用P2X4受体抑制剂或小胶质细胞激活抑制剂作为活性成分。

公开(公告)号：US5747274A

公开(公告)日：1998-05-05

申请号：US697690

申请日：1996-09-05

申请人： George Jackowski

发明人： George Jackowski

IPC分类号： G01N33/53 ,  C07K16/42 ,  G01N33/573 ,  G01N33/68 ,  G01N33/558

CPC分类号： C07K16/4283 ,  G01N33/573 ,  G01N33/6887 ,  G01N33/6893 ,  G01N2800/2842 ,  G01N2800/32 ,  G01N2800/324 ,  Y10S435/97 ,  Y10S435/973 ,  Y10S435/975 ,  Y10S436/807 ,  Y10S436/808 ,  Y10S436/81 ,  Y10S436/811

摘要： A diagnostic test, and a device for conducting the test, for assessing whether patient chest pain is cardiac in origin and for differentiating between unstable angina and myocardial infarction as a cause of patient chest pain is described. The diagnostic test comprises simultaneously detecting at least three selected cardiac markers with the use of at least three different monoclonal or polyclonal antibody pairs, each member of which is complementary to a different marker, which is released by heart muscle at varying stages after the onset of chest pain and is indicative of the cause of the chest pain.

公开(公告)号：US20180348233A1

公开(公告)日：2018-12-06

申请号：US16002689

申请日：2018-06-07

申请人： EPICGENETICS, INC.

发明人： Bruce S. GILLIS

IPC分类号： G01N33/68

CPC分类号： G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/523 ,  G01N2333/5409 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5428 ,  G01N2333/57 ,  G01N2800/10 ,  G01N2800/2842 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/60 ,  G01N2800/7095

摘要： The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of FM in the individual.